全文获取类型
收费全文 | 7697篇 |
免费 | 547篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 117篇 |
妇产科学 | 176篇 |
基础医学 | 962篇 |
口腔科学 | 222篇 |
临床医学 | 807篇 |
内科学 | 1848篇 |
皮肤病学 | 147篇 |
神经病学 | 641篇 |
特种医学 | 678篇 |
外科学 | 1376篇 |
综合类 | 36篇 |
预防医学 | 232篇 |
眼科学 | 156篇 |
药学 | 348篇 |
中国医学 | 2篇 |
肿瘤学 | 461篇 |
出版年
2024年 | 12篇 |
2023年 | 105篇 |
2022年 | 188篇 |
2021年 | 332篇 |
2020年 | 201篇 |
2019年 | 294篇 |
2018年 | 321篇 |
2017年 | 236篇 |
2016年 | 263篇 |
2015年 | 315篇 |
2014年 | 415篇 |
2013年 | 411篇 |
2012年 | 627篇 |
2011年 | 631篇 |
2010年 | 378篇 |
2009年 | 365篇 |
2008年 | 454篇 |
2007年 | 428篇 |
2006年 | 348篇 |
2005年 | 310篇 |
2004年 | 256篇 |
2003年 | 246篇 |
2002年 | 181篇 |
2001年 | 99篇 |
2000年 | 79篇 |
1999年 | 97篇 |
1998年 | 33篇 |
1997年 | 41篇 |
1996年 | 28篇 |
1995年 | 18篇 |
1994年 | 13篇 |
1993年 | 15篇 |
1992年 | 32篇 |
1991年 | 31篇 |
1990年 | 25篇 |
1989年 | 21篇 |
1988年 | 26篇 |
1987年 | 31篇 |
1986年 | 26篇 |
1985年 | 25篇 |
1984年 | 15篇 |
1983年 | 15篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1979年 | 23篇 |
1975年 | 12篇 |
1932年 | 13篇 |
1931年 | 8篇 |
1924年 | 12篇 |
1922年 | 8篇 |
排序方式: 共有8278条查询结果,搜索用时 0 毫秒
41.
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. 总被引:14,自引:0,他引:14
Philipp Str?bel Andrea Bauer Bernhard Puppe Til Kraushaar Axel Krein Klaus Toyka Ralf Gold Michael Semik Reinhard Kiefer Wilfred Nix Berthold Schalke Hans Konrad Müller-Hermelink Alexander Marx 《Journal of clinical oncology》2004,22(8):1501-1509
PURPOSE: Thymic epithelial tumors (TET) are rare epithelial neoplasms of the thymus with considerable histologic heterogeneity. This retrospective study focused on the correlation of WHO-defined TET histotypes with survival and tumor recurrence in a large cohort of patients receiving different modes of treatment. PATIENTS AND METHODS: Two hundred twenty-eight patients were followed for up to 21 years (median, 60 months; range, 1 to 252 months) after primary surgery. Forty-two patients received adjuvant radiotherapy (mean dose, 53 Gy), and 33 patients received adjuvant chemotherapy. RESULTS: Seventy-six (88%) of 86 patients with WHO type A, AB, and B1 thymomas were treated by surgery alone, with three tumor relapses after 3 to 10 years (median, 3.4 years). Twelve of 67 patients with WHO type B2 and B3 thymomas in Masaoka stages I and II were treated by adjuvant radiotherapy without evidence of tumor recurrence after 1 to 12 years (median, 4 years). Among 75 patients with B2 and B3 thymomas with incomplete resection or a tumor stage III or higher, the recurrence rate was 34% (n = 23) after 0.5 to 17 years (median, 5 years) in patients receiving adjuvant radiochemotherapy, compared to 78% (seven of nine patients) in patients without adjuvant radiochemotherapy. Incomplete tumor resection was associated with a high recurrence rate (65%) and a poor prognosis (P <.01). CONCLUSION: The long-term outcome of TET patients is related to tumor stage, WHO histotype, completeness of surgical removal, and type of treatment. Prospective trials are warranted to formally address the efficacy of adjuvant therapy in the treatment of localized and advanced malignant TETs. 相似文献
42.
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. 总被引:5,自引:0,他引:5
Hans Herbert Steiner Matteo Mario Bonsanto Philipp Beckhove Michael Brysch Karsten Geletneky Rezvan Ahmadi Rebecca Schuele-Freyer Paul Kremer Golamreza Ranaie Dejana Matejic Harald Bauer Marika Kiessling Stefan Kunze Volker Schirrmacher Christel Herold-Mende 《Journal of clinical oncology》2004,22(21):4272-4281
PURPOSE: Prognosis of patients with glioblastoma is poor. Therefore, in glioblastoma patients, we analyzed whether antitumor vaccination with a virus-modified autologous tumor cell vaccine is feasible and safe. Also, we determined the influence on progression-free survival and overall survival and on vaccination-induced antitumor reactivity. PATIENTS AND METHODS: In a nonrandomized study, 23 patients were vaccinated and compared with nonvaccinated controls (n = 87). Vaccine was prepared from patient's tumor cell cultures by infection of the cells with Newcastle Disease Virus, followed by gamma-irradiation, and applied up to eight times. Antitumor immune reactivity was determined in skin, blood, and relapsed tumor by delayed-type hypersensitivity skin reaction, ELISPOT assay, and immunohistochemistry, respectively. RESULTS: Establishment of tumor cell cultures was successful in approximately 90% of patients. After vaccination, we observed no severe side effects. The median progression-free survival of vaccinated patients was 40 weeks (v 26 weeks in controls; log-rank test, P = .024), and the median overall survival of vaccinated patients was 100 weeks (v 49 weeks in controls; log-rank test, P < .001). Forty-five percent of the controls survived 1 year, 11% survived 2 years, and there were no long-term survivors (> or = 3 years). Ninety-one percent of vaccinated patients survived 1 year, 39% survived 2 years, and 4% were long-term survivors. In the vaccinated group, immune monitoring revealed significant increases of delayed-type hypersensitivity reactivity, numbers of tumor-reactive memory T cells, and numbers of CD8(+) tumor-infiltrating T-lymphocytes in secondary tumors. CONCLUSION: Postoperative vaccination with virus-modified autologous tumor cells seems to be feasible and safe and to improve the prognosis of patients with glioblastomas. This could be substantiated by the observed antitumor immune response. 相似文献
43.
Herget-Rosenthal S Trabold S Pietruck F Holtmann M Philipp T Kribben A 《American journal of nephrology》2000,20(2):97-102
Serum cystatin C, a cysteine proteinase inhibitor, has been proposed as a marker of glomerular filtration rate (GFR). Serum cystatin C, serum creatinine and creatinine clearance were measured in 226 patients with various nephropathies, covering the entire range of renal function, to evaluate the efficacy of cystatin C as a screening test to detect reduced creatinine clearance in comparison to creatinine. Subgroups of 53 patients with glomerular and 26 patients with tubular impairment were compared to assess whether cystatin C performed differently in either glomerular or tubular impairment. Cystatin C detected reduced creatinine clearance with higher sensitivity (97 vs. 83%), and higher negative predictive value (96 vs. 87%) compared to creatinine. In parallel, 95% sensitivity of cystatin C as derived from receiver-operating characteristic plot was significantly higher (p < 0.05). In the subgroups with glomerular or tubular impairment, cystatin C and creatinine did not significantly differ with regard to efficacy. Serum cystatin C is as efficacious as serum creatinine to detect reduced GFR as measured by creatinine clearance. The efficacy of cystatin C as a screening test may even be superior compared to creatinine. In addition, the efficacy of cystatin C is independent of either glomerular or tubular impairment. 相似文献
44.
45.
46.
Paul M Garrett Joshua P White Simon Dennis Stephan Lewandowsky Cheng-Ta Yang Yasmina Okan Andrew Perfors Daniel R Little Anastasia Kozyreva Philipp Lorenz-Spreen Takashi Kusumi Yoshihisa Kashima 《JMIR Public Health and Surveillance》2022,8(7)
BackgroundIn response to the COVID-19 pandemic, countries are introducing digital passports that allow citizens to return to normal activities if they were previously infected with (immunity passport) or vaccinated against (vaccination passport) SARS-CoV-2. To be effective, policy decision-makers must know whether these passports will be widely accepted by the public and under what conditions. This study focuses attention on immunity passports, as these may prove useful in countries both with and without an existing COVID-19 vaccination program; however, our general findings also extend to vaccination passports.ObjectiveWe aimed to assess attitudes toward the introduction of immunity passports in six countries, and determine what social, personal, and contextual factors predicted their support.MethodsWe collected 13,678 participants through online representative sampling across six countries—Australia, Japan, Taiwan, Germany, Spain, and the United Kingdom—during April to May of the 2020 COVID-19 pandemic, and assessed attitudes and support for the introduction of immunity passports.ResultsImmunity passport support was moderate to low, being the highest in Germany (775/1507 participants, 51.43%) and the United Kingdom (759/1484, 51.15%); followed by Taiwan (2841/5989, 47.44%), Australia (963/2086, 46.16%), and Spain (693/1491, 46.48%); and was the lowest in Japan (241/1081, 22.94%). Bayesian generalized linear mixed effects modeling was used to assess predictive factors for immunity passport support across countries. International results showed neoliberal worldviews (odds ratio [OR] 1.17, 95% CI 1.13-1.22), personal concern (OR 1.07, 95% CI 1.00-1.16), perceived virus severity (OR 1.07, 95% CI 1.01-1.14), the fairness of immunity passports (OR 2.51, 95% CI 2.36-2.66), liking immunity passports (OR 2.77, 95% CI 2.61-2.94), and a willingness to become infected to gain an immunity passport (OR 1.6, 95% CI 1.51-1.68) were all predictive factors of immunity passport support. By contrast, gender (woman; OR 0.9, 95% CI 0.82-0.98), immunity passport concern (OR 0.61, 95% CI 0.57-0.65), and risk of harm to society (OR 0.71, 95% CI 0.67-0.76) predicted a decrease in support for immunity passports. Minor differences in predictive factors were found between countries and results were modeled separately to provide national accounts of these data.ConclusionsOur research suggests that support for immunity passports is predicted by the personal benefits and societal risks they confer. These findings generalized across six countries and may also prove informative for the introduction of vaccination passports, helping policymakers to introduce effective COVID-19 passport policies in these six countries and around the world. 相似文献
47.
Philipp Saiko Geraldine Graser Benedikt Giessrigl Andreas Lackner Michael Grusch Georg Krupitza Arijit Basu Barij Nayan Sinha Venkatesan Jayaprakash Walter Jaeger Monika Fritzer-Szekeres Thomas Szekeres 《Biochemical pharmacology》2011,(1):50
Ribonucleotide reductase (RR; EC 1.17.4.1) is responsible for the de novo conversion of ribonucleoside diphosphates into deoxyribonucleoside diphosphates, which are essential for DNA replication. RR is upregulated in tumor cells and therefore considered to be an excellent target for cancer chemotherapy.ABNM-13 (N-hydroxy-2-(anthracene-2-yl-methylene)-hydrazinecarboximidamide), a novel N-hydroxy-N′-aminoguanidine has been designed to inhibit RR activity using 3D molecular space modeling techniques. In this study, we evaluated its effect on human HL-60 promyelocytic leukemia cells. ABNM-13 proved to be a potent inhibitor of RR which was displayed by significant alterations of deoxyribonucleoside triphosphate (dNTP) pool balance and a highly significant decrease of incorporation of radiolabeled cytidine into DNA of HL-60 cells. Diminished RR activity caused replication stress which was consistent with activation of Chk1 and Chk2, resulting in downregulation/degradation of Cdc25A. In contrast, Cdc25B was upregulated, leading to dephosphorylation and activation of Cdk1. The combined disregulation of Cdc25A and Cdc25B was the most likely cause for ABNM-13 induced S-phase arrest. Finally, we combined ABNM-13 with the first-line antileukemic agent arabinofuranosylcytosine (Ara-C) and found that ABNM-13 synergistically potentiated the antineoplastic effects of Ara-C.Due to these promising results, ABNM-13 deserves further preclinical and in vivo testing. 相似文献
48.
49.
A. Simons Fritz Händel Langendorff Josef Frank F. Eillinger Happel Zwerg Fried Walter Schaefer Hedfeld E. Philipp Wehefritz Englmann 《Journal of cancer research and clinical oncology》1932,36(5-6):125-128
Ohne Zusammenfassung 相似文献
50.
E. Philipp H. J. Arndt I. Costero Erich Müller C. Kaufmann 《Journal of cancer research and clinical oncology》1931,34(5):174-177
Ohne Zusammenfassung 相似文献